Doença associada ao Clostridioides difficile

Referências

Principais artigos

McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 Mar 19;66(7):e1-e48.Texto completo  Resumo

Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021 Jun 24:ciab549.Texto completo  Resumo

van Prehn J, Reigadas E, Vogelzang EH, et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect. 2021 Dec;27 Suppl 2:S1-S21.Texto completo  Resumo

Beinortas T, Burr NE, Wilcox MH, et al. Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis. Lancet Infect Dis. 2018 Sep;18(9):1035-44. Resumo

Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev. 2017;(3):CD004610.Texto completo  Resumo

Artigos de referência

1. Lawson PA, Citron DM, Tyrrell KL, et al. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Prévot 1938. Anaerobe. 2016 Aug;40:95-9. Resumo

2. McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 Mar 19;66(7):e1-e48.Texto completo  Resumo

3. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ. 2004 Jul 6;171(1):51-8.Texto completo  Resumo

4. Balsells E, Shi T, Leese C, et al. Global burden of Clostridium difficile infections: a systematic review and meta-analysis. J Glob Health. 2019 Jun;9(1):010407.Texto completo  Resumo

5. Turner NA, Grambow SC, Woods CW, et al. Epidemiologic trends in Clostridioides difficile infections in a regional community hospital network. JAMA Netw Open. 2019 Oct 2;2(10):e1914149.Texto completo  Resumo

6. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015 Feb 26;372(9):825-34.Texto completo  Resumo

7. Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis. 2021 May 19;21(1):456.Texto completo  Resumo

8. Abrahamian FM, Talan DA, Krishnadasan A, et al; EMERGEncy ID NET Study Group. Clostridium difficile infection among US emergency department patients with diarrhea and no vomiting. Ann Emerg Med. 2017 Jul;70(1):19-27;e4. Resumo

9. Bartlett JG, Perl TM. The new Clostridium difficile - what does it mean? N Engl J Med. 2005 Dec 8;353(23):2503-5. Resumo

10. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005 Dec 8;353(23):2442-9.Texto completo  Resumo

11. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005 Dec 8;353(23):2433-41.Texto completo  Resumo

12. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006 Nov 21;145(10):758-64. Resumo

13. Carlson TJ, Blasingame D, Gonzales-Luna AJ, et al. Clostridioides difficile ribotype 106: a systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain. Anaerobe. 2020 Apr;62:102142. Resumo

14. Sheitoyan-Pesant C, Abou Chakra CN, Pépin J, et al. Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection. Clin Infect Dis. 2016 Mar 1;62(5):574-80.Texto completo  Resumo

15. Ma GK, Brensinger CM, Wu Q, et al. Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: a cohort study. Ann Intern Med. 2017 Aug 1;167(3):152-8. Resumo

16. van Rossen TM, Ooijevaar RE, Vandenbroucke-Grauls CMJE, et al. Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review. Clin Microbiol Infect. 2022 Mar;28(3):321-31.Texto completo  Resumo

17. Mehta P, Nahass RG, Brunetti L. Acid suppression medications during hospitalization as a risk factor for recurrence of clostridioides difficile Infection: systematic review and meta-analysis. Clin Infect Dis. 2021 Jul 1;73(1):e62-8.Texto completo  Resumo

18. UK Health Security Agency. C. difficile infection: monthly data by prior trust exposure. Jun 2023 [internet publication].Texto completo

19. European Centre for Disease Prevention and Control. Healthcare-associated infections: Clostridium difficile infections - annual epidemiological report for 2016-2017. Nov 2022 [internet publication].​Texto completo

20. Borren NZ, Ghadermarzi S, Hutfless S, et al. The emergence of Clostridium difficile infection in Asia: a systematic review and meta-analysis of incidence and impact. PLoS One. 2017 May 2;12(5):e0176797.Texto completo  Resumo

21. Treatment of Clostridium difficile infection. Med Lett Drugs Ther. 2011 Feb 21;53(1358):14-5. Resumo

22. Schroeder MS. Clostridium difficile-associated diarrhea. Am Fam Physician. 2005 Mar 1;71(5):921-8.Texto completo  Resumo

23. Anjewierden S, Han Z, Brown AM, et al. Risk factors for Clostridioides difficile colonization among hospitalized adults: a meta-analysis and systematic review. Infect Control Hosp Epidemiol. 2021 May;42(5):565-72. Resumo

24. Miller AC, Segre AM, Pemmaraju SV, et al. Association of household exposure to primary Clostridioides difficile infection with secondary infection in family members. JAMA Netw Open. 2020 Jun 1;3(6):e208925.Texto completo  Resumo

25. Slimings C, Riley TV. Antibiotics and healthcare facility-associated Clostridioides difficile infection: systematic review and meta-analysis 2020 update. J Antimicrob Chemother. 2021 Jun 18;76(7):1676-88.Texto completo  Resumo

26. Teng C, Reveles KR, Obodozie-Ofoegbu OO, et al Clostridium difficile infection risk with important antibiotic classes: an analysis of the FDA Adverse Event Reporting System. Int J Med Sci. 2019 May 7;16(5):630-5.Texto completo  Resumo

27. Tariq R, Cho J, Kapoor S, et al. Low risk of primary Clostridium difficile infection with tetracyclines: a systematic review and metaanalysis. Clin Infect Dis. 2018 Feb 1;66(4):514-22. Resumo

28. Dingle KE, Didelot X, Quan TP, et al. Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infect Dis. 2017 Apr;17(4):411-21.Texto completo  Resumo

29. Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017 Sep;17(9):990-1001. Resumo

30. Blumenthal KG, Lu N, Zhang Y, et al. Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study. BMJ. 2018 Jun 27;361:k2400.Texto completo  Resumo

31. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005 Dec 8;353(23):2442-9.Texto completo  Resumo

32. Blixt T, Gradel KO, Homann C, et al. Asymptomatic carriers contribute to nosocomial Clostridium difficile infection: a cohort study of 4508 patients. Gastroenterology. 2017 Apr;152(5):1031-41;e2. Resumo

33. Miller AC, Segre AM, Pemmaraju SV, et al. Association of household exposure to primary Clostridioides difficile infection with secondary infection in family members. JAMA Netw Open. 2020 Jun 1;3(6):e208925.Texto completo  Resumo

34. Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003 Jul;54(3):243-5. Resumo

35. US Food and Drug Administration. FDA drug safety communication: Clostridium difficile associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Feb 2012 [internet publication].Texto completo

36. Arriola V, Tischendorf J, Musuuza J, et al. Assessing the risk of hospital-acquired clostridium difficile infection with proton pump inhibitor use: a meta-analysis. Infect Control Hosp Epidemiol. 2016 Dec;37(12):1408-17.Texto completo  Resumo

37. Oshima T, Wu L, Li M, et al. Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis. J Gastroenterol. 2018 Jan;53(1):84-94. Resumo

38. Cao F, Chen CX, Wang M, et al. Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection. J Hosp Infect. 2018 Jan;98(1):4-13. Resumo

39. Azab M, Doo L, Doo DH, et al. Comparison of the hospital-acquired Clostridium difficile infection risk of using proton pump inhibitors versus histamine-2 receptor antagonists for prophylaxis and treatment of stress ulcers: a systematic review and meta-analysis. Gut Liver. 2017 Nov 15;11(6):781-8.Texto completo  Resumo

40. Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008 Jun;103(6):1443-50. Resumo

41. Razik R, Rumman A, Bahreini Z, et al. Recurrence of Clostridium difficile infection in ptients with inflammatory bowel disease: the RECIDIVISM study. Am J Gastroenterol. 2016 Aug;111(8):1141-6. Resumo

42. Tariq R, Law CCY, Khanna S, et al. The impact of Clostridium difficile infection on mortality in patients with inflammatory bowel disease: a systematic review and meta-analysis. J Clin Gastroenterol. 2019 Feb;53(2):127-33. Resumo

43. Balram B, Battat R, Al-Khoury A, et al. Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2019 Jan 1;13(1):27-38.Texto completo  Resumo

44. Donnelly JP, Wang HE, Locke JE, et al. Hospital-onset Clostridium difficile infection among solid organ transplant recipients. Am J Transplant. 2015 Nov;15(11):2970-7.Texto completo  Resumo

45. Paudel S, Zacharioudakis IM, Zervou FN, et al. Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies. PLoS One. 2015 Apr 17;10(4):e0124483.Texto completo  Resumo

46. Zacharioudakis IM, Ziakas PD, Mylonakis E. Clostridium difficile infection in the hematopoietic unit: a meta-analysis of published studies. Biol Blood Marrow Transplant. 2014 Oct;20(10):1650-4.Texto completo  Resumo

47. Luo Y, Zhang S, Shang H, et al. Prevalence of Clostridium difficile infection in the hematopoietic transplantation setting: update of systematic review and meta-analysis. Front Cell Infect Microbiol. 2022;12:801475.Texto completo  Resumo

48. Phatharacharukul P, Thongprayoon C, Cheungpasitporn W, et al. The risks of incident and recurrent Clostridium difficile-associated diarrhea in chronic kidney disease and end-stage kidney disease patients: a systematic review and meta-analysis. Dig Dis Sci. 2015 Oct;60(10):2913-22. Resumo

49. Sanchez TH, Brooks JT, Sullivan PS, et al; Adult/Adolescent Spectrum of HIV Disease Study Group. Bacterial diarrhea in persons with HIV infection, United States, 1992-2002. Clin Infect Dis. 2005 Dec 1;41(11):1621-7.Texto completo  Resumo

50. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis. 1993 Jul;17(1):109-13. Resumo

51. Li Y, Cai H, Sussman DA, et al. Association between immunosuppressive therapy and outcome of Clostridioides difficile infection: systematic review and meta-analysis. Dig Dis Sci. 2022 Aug;67(8):3890-903. Resumo

52. Southern WN, Rahmani R, Aroniadis O, et al. Postoperative Clostridium difficile-associated diarrhea. Surgery. 2010 Jul;148(1):24-30.Texto completo  Resumo

53. Khorasani S, Dossa F, McKechnie T, et al. Association between preoperative oral antibiotics and the incidence of postoperative Clostridium difficile infection in adults undergoing elective colorectal resection: a systematic review and meta-analysis. Dis Colon Rectum. 2020 Apr;63(4):545-61. Resumo

54. Harries RL, Ansell J, Codd RJ, et al. A systematic review of Clostridium difficile infection following reversal of ileostomy. Colorectal Dis. 2017 Oct;19(10):881-7. Resumo

55. Furuya-Kanamori L, Wangdi K, Yakob L, et al. 25-hydroxyvitamin D concentrations and Clostridium difficile infection: a meta-analysis. JPEN J Parenter Enteral Nutr. 2017 Jul;41(5):890-5. Resumo

56. Su GL, Ko CW, Bercik P, et al. AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. Gastroenterology. 2020 Aug;159(2):697-705. Resumo

57. Kelly CR, Fischer M, Allegretti JR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021 Jun 1;116(6):1124-47. Resumo

58. McFarland LV, Kullar R, Johnson S, et al. Why do ACG and AGA guidelines differ for the use of probiotics and the prevention of CDI? Am J Gastroenterol. 2022 Mar 1;117(3):501. Resumo

59. Goldenberg JZ, Yap C, Lytvyn L, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017 Dec 19;12:CD006095.Texto completo  Resumo

60. Shen NT, Maw A, Tmanova LL, et al. Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology. 2017 Jun;152(8):1889-900;e9.Texto completo  Resumo

61. Ma Y, Yang JY, Peng X, et al. Which probiotic has the best effect on preventing Clostridium difficile-associated diarrhea? A systematic review and network meta-analysis. J Dig Dis. 2020 Feb;21(2):69-80. Resumo

62. Deschênes P, Chano F, Dionne LL, et al. Efficacy of the World Health Organization-recommended handwashing technique and a modified washing technique to remove Clostridium difficile from hands. Am J Infect Control. 2017 Aug 1;45(8):844-8. Resumo

63. Banach DB, Bearman G, Barnden M, et al. Duration of contact precautions for acute-care settings. Infect Control Hosp Epidemiol. 2018 Feb;39(2):127-44.Texto completo  Resumo

64. Rutala WA, Weber DJ. Sterilization, high-level disinfection, and environmental cleaning. Infect Dis Clin North Am. 2011 Mar;25(1):45-76. Resumo

65. National Institute for Health and Care Excellence. Infection prevention and control. Apr 2014 [internet publication].Texto completo

66. Kato H, Hagihara M, Asai N, et al. A systematic review and meta-analysis of decontamination methods to prevent hospital environmental contamination and transmission of Clostridioidesdifficile. Anaerobe. 2022 Feb;73:102478. Resumo

67. Lewis SR, Schofield-Robinson OJ, Rhodes S, et al. Chlorhexidine bathing of the critically ill for the prevention of hospital-acquired infection. Cochrane Database Syst Rev. 2019 Aug 30;8(8):CD012248.Texto completo  Resumo

68. Alshrari AS, Hudu SA, Elmigdadi F, et al. The urgent threat of Clostridioides difficile infection: a glimpse of the drugs of the future, with related patents and prospects. Biomedicines. 2023 Feb 1;11(2):426.Texto completo  Resumo

69. Tschudin-Sutter S, Kuijper EJ, Durovic A, et al. Guidance document for prevention of Clostridium difficile infection in acute healthcare settings. Clin Microbiol Infect. 2018 Oct;24(10):1051-4.Texto completo  Resumo

70. Arimoto J, Horita N, Kato S, et al. Diagnostic test accuracy of glutamate dehydrogenase for Clostridium difficile: systematic review and meta-analysis. Sci Rep. 2016 Jul 15;6:29754.Texto completo  Resumo

71. Deshpande A, Pasupuleti V, Pant C, et al. Potential value of repeat stool testing for Clostridium difficile stool toxin using enzyme immunoassay? Curr Med Res Opin. 2010 Nov;26(11):2635-41.Texto completo  Resumo

72. Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021 Jun 24:ciab549.Texto completo  Resumo

73. Zhang VRY, Woo ASJ, Scaduto C, et al. Systematic review on the definition and predictors of severe Clostridiodes difficile infection. J Gastroenterol Hepatol. 2021 Jan;36(1):89-104.Texto completo  Resumo

74. Bishop EJ, Tiruvoipati R. Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines. J Antimicrob Chemother. 2022 Dec 23;78(1):21-30.Texto completo  Resumo

75. National Institute for Health and Care Excellence. Clostridioides difficile infection: antimicrobial prescribing NICE guideline [NG199]. 23 Jul 2021 [internet publication].Texto completo

76. van Prehn J, Reigadas E, Vogelzang EH, et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect. 2021 Dec;27 Suppl 2:S1-S21.Texto completo  Resumo

77. Beinortas T, Burr NE, Wilcox MH, et al. Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis. Lancet Infect Dis. 2018 Sep;18(9):1035-44. Resumo

78. Okumura H, Fukushima A, Taieb V, et al. Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: a network meta-analysis. J Infect Chemother. 2020 Jan;26(1):43-50.Texto completo  Resumo

79. Tashiro S, Mihara T, Sasaki M, et al. Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: a systematic review and meta-analysis of randomized controlled trials. J Infect Chemother. 2022 Nov;28(11):1536-45. Resumo

80. Liao JX, Appaneal HJ, Vicent ML, et al. Path of least recurrence: a systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection. Pharmacotherapy. 2022 Nov;42(11):810-27. Resumo

81. Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev. 2017;(3):CD004610.Texto completo  Resumo

82. Khanna S, Shin A, Kelly CP. Management of Clostridium difficile infection in inflammatory bowel disease: expert review from the Clinical Practice Updates Committee of the AGA Institute. Clin Gastroenterol Hepatol. 2017 Feb;15(2):166-74.Texto completo  Resumo

83. D'Aoust J, Battat R, Bessissow T. Management of inflammatory bowel disease with Clostridium difficile infection. World J Gastroenterol. 2017 Jul 21;23(27):4986-5003.Texto completo  Resumo

84. Cimolai N. Does oral vancomycin use necessitate therapeutic drug monitoring? Infection. 2020 Apr;48(2):173-82. Resumo

85. Sholeh M, Krutova M, Forouzesh M, et al. Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2020 Sep 25;9(1):158.Texto completo  Resumo

86. Ng QX, Loke W, Foo NX, et al. A systematic review of the use of rifaximin for Clostridium difficile infections. Anaerobe. 2019 Feb;55:35-9. Resumo

87. Kechagias KS, Chorepsima S, Triarides NA, et al. Tigecycline for the treatment of patients with Clostridium difficile infection: an update of the clinical evidence. Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1053-8. Resumo

88. Jaber MR, Olafsson S, Fung WL, et al. Clinical review of the management of fulminant Clostridium difficile infection. Am J Gastroenterol. 2008 Dec;103(12):3195-203;quiz 3204. Resumo

89. Forrester JD, Colling KP, Diaz JJ, et al. Surgical Infection Society guidelines for total abdominal colectomy versus diverting loop ileostomy with antegrade intra-colonic lavage for the surgical management of severe or fulminant, non-perforated Clostridioides difficile Colitis. Surg Infect (Larchmt). 2022 Mar;23(2):97-104. Resumo

90. Felsenreich DM, Gachabayov M, Rojas A, et al. Meta-analysis of postoperative mortality and morbidity after total abdominal colectomy versus loop ileostomy with colonic lavage for fulminant Clostridium difficile colitis. Dis Colon Rectum. 2020 Sep;63(9):1317-26. Resumo

91. McKechnie T, Lee Y, Springer JE, et al. Diverting loop ileostomy with colonic lavage as an alternative to colectomy for fulminant Clostridioides difficile: a systematic review and meta-analysis. Int J Colorectal Dis. 2020 Jan;35(1):1-8. Resumo

92. Singh T, Bedi P, Bumrah K, et al. Fecal microbiota transplantation and medical therapy for Clostridium difficile infection : meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2022 Nov-Dec 01;56(10):881-8. Resumo

93. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011 Feb 3;364(5):422-31.Texto completo  Resumo

94. Stevens VW, Nelson RE, Schwab-Daugherty EM, et al. Comparative effectiveness of vancomycin and metronidazole for the prevention of recurrence and death in patients with Clostridium difficile infection. JAMA Intern Med. 2017 Apr 1;177(4):546-53. Resumo

95. Sehgal K, Zandvakili I, Tariq R, et al. Systematic review and meta-analysis: efficacy of vancomycin taper and pulse regimens in Clostridioides difficile infection. Expert Rev Anti Infect Ther. 2022 Apr;20(4):577-83. Resumo

96. Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017 Jan 26;376(4):305-17.Texto completo  Resumo

97. Alhifany AA, Almutairi AR, Almangour TA, et al. Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent Clostridium difficile infections: a systematic review and Bayesian network meta-analysis of randomised controlled trials. BMJ Open. 2019 Nov 7;9(11):e031145.Texto completo  Resumo

98. National Institute for Health and Care Excellence. Faecal microbiota transplant for recurrent Clostridioides difficile infection. Aug 2022 [internet publication].Texto completo

99. Minkoff NZ, Aslam S, Medina M, et al. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile). Cochrane Database Syst Rev. 2023 Apr 25;4(4):CD013871.Texto completo  Resumo

100. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013 Jan 31;368(5):407-15.Texto completo  Resumo

101. Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016 Jan 12;315(2):142-9.Texto completo  Resumo

102. Hota SS, Sales V, Tomlinson G, et al. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile infection: an open-label, randomized controlled trial. Clin Infect Dis. 2017 Feb 1;64(3):265-71.Texto completo  Resumo

103. Lai CY, Sung J, Cheng F, et al. Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation. Aliment Pharmacol Ther. 2019 Feb;49(4):354-63. Resumo

104. Du C, Luo Y, Walsh S, et al. Oral fecal microbiota transplant capsules are safe and effective for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. J Clin Gastroenterol. 2021 Apr 1;55(4):300-8. Resumo

105. Kelly CR, Yen EF, Grinspan AM, et al. Fecal microbiota transplantation Is highly effective in real-world practice: initial results from the FMT National Registry. Gastroenterology. 2021 Jan; 160(1):183-92.e3.Texto completo  Resumo

106. Tariq R, Pardi DS, Bartlett MG, et al. Low cure rates in controlled trials of fecal microbiota transplantation for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Clin Infect Dis. 2019 Apr 8;68(8):1351-8.Texto completo  Resumo

107. Rokkas T, Gisbert JP, Gasbarrini A, et al. A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection. United European Gastroenterol J. 2019 Oct;7(8):1051-63.Texto completo  Resumo

108. Hui W, Li T, Liu W, et al. Fecal microbiota transplantation for treatment of recurrent C. difficile infection: an updated randomized controlled trial meta-analysis. PLoS One. 2019 Jan 23;14(1):e0210016.Texto completo  Resumo

109. Baunwall SMD, Andreasen SE, Hansen MM, et al. Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2022 Sep 21:S2468-1253(22)00276-X. Resumo

110. Moayyedi P, Yuan Y, Baharith H, et al. Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: a systematic review of randomised controlled trials. Med J Aust. 2017 Aug 21;207(4):166-72.Texto completo  Resumo

111. Hvas CL, Dahl Jørgensen SM, Jørgensen SP, et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology. 2019 Apr;156(5):1324-32.e3.Texto completo  Resumo

112. Beran A, Sharma S, Ghazaleh S, et al. Predictors of fecal microbiota transplant failure in Clostridioides difficile infection : an updated meta-analysis. J Clin Gastroenterol. 2023 Apr 1;57(4):389-99. Resumo

113. Ramai D, Zakhia K, Fields PJ, et al. Fecal microbiota transplantation (FMT) with colonoscopy is superior to enema and nasogastric tube while comparable to capsule for the treatment of recurrent Clostridioides difficile infection: a systematic review and meta-analysis. Dig Dis Sci. 2021 Feb;66(2):369-80. Resumo

114. Tang G, Yin W, Liu W. Is frozen fecal microbiota transplantation as effective as fresh fecal microbiota transplantation in patients with recurrent or refractory Clostridium difficile infection: a meta-analysis? Diagn Microbiol Infect Dis. 2017 Aug;88(4):322-9. Resumo

115. Furuya-Kanamori L, Doi SA, Paterson DL, et al. Upper versus lower gastrointestinal delivery for transplantation of fecal microbiota in recurrent or refractory Clostridium difficile infection: a collaborative analysis of individual patient data from 14 studies. J Clin Gastroenterol. 2017 Feb;51(2):145-50. Resumo

116. Gangwani MK, Aziz M, Aziz A, et al. Fresh versus frozen versus lyophilized fecal microbiota transplant for recurrent Clostridium difficile infection: a systematic review and network meta-analysis. J Clin Gastroenterol. 2023 Mar 1;57(3):239-45. Resumo

117. Wang S, Xu M, Wang W, et al. Systematic review: adverse events of fecal microbiota transplantation. PLoS One. 2016 Aug 16;11(8):e0161174.Texto completo  Resumo

118. Marcella C, Cui B, Kelly CR, et al. Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020. Aliment Pharmacol Ther. 2021 Jan;53(1):33-42. Resumo

119. Pomares Bascuñana RÁ, Veses V, Sheth CC. Effectiveness of fecal microbiota transplant for the treatment of Clostridioides difficile diarrhea: a systematic review and meta-analysis. Lett Appl Microbiol. 2021 Aug;73(2):149-58.Texto completo  Resumo

120. Khoruts A, Rank KM, Newman KM, et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2016 Oct; 14(10):1433-8.Texto completo  Resumo

121. Chen T, Zhou Q, Zhang D, et al. Effect of faecal microbiota transplantation for treatment of Clostridium difficile infection in patients with inflammatory bowel disease: a systematic review and meta-analysis of cohort studies. J Crohns Colitis. 2018 May 25;12(6):710-7.Texto completo  Resumo

122. Tariq R, Syed T, Yadav D, et al. Outcomes of fecal microbiota transplantation for C. difficile infection in inflammatory bowel disease : a systematic review and meta-analysis. J Clin Gastroenterol. 2023 Mar 1;57(3):285-93. Resumo

123. Shogbesan O, Poudel DR, Victor S, et al. A systematic review of the efficacy and safety of fecal microbiota transplant for Clostridium difficile infection in immunocompromised patients. Can J Gastroenterol Hepatol. 2018 Sep 2;2018:1394379.Texto completo  Resumo

124. US Food and Drug Administration. Important safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant organisms. Jun 2019 [internet publication].Texto completo

125. US Food and Drug Administration. Fecal microbiota for transplantation: safety alert - risk of serious adverse events likely due to transmission of pathogenic organisms. Apr 2020 [internet publication].Texto completo

126. US Food and Drug Administration. Safety alert regarding use of fecal microbiota for transplantation and additional safety protections pertaining to monkeypox virus. Aug 2022 [internet publication].Texto completo

127. Ianiro G, Murri R, Sciumè GD, et al. Incidence of bloodstream infections, length of hospital stay, and survival in patients with recurrent Clostridioides difficile infection treated with fecal microbiota transplantation or antibiotics: a prospective cohort study. Ann Intern Med. 2019 Nov 19;171(10):695-702. Resumo

128. Bafeta A, Yavchitz A, Riveros C, et al. Methods and reporting studies assessing fecal microbiota transplantation: a systematic review. Ann Intern Med. 2017 Jul 4;167(1):34-9. Resumo

129. Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 2022 Jan 20;386(3):220-9.Texto completo  Resumo

130. Louie T, Golan Y, Khanna S, et al. VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial. JAMA. 2023 Apr 25;329(16):1356-66. Resumo

131. ClinicalTrials.gov. Exploratory study to assess delivery of LMN-201 components via enteric capsules in the gut of individuals with ostomies. ClinicalTrials.gov identifier: NCT04893239. Mar 2022 [internet publication].Texto completo

132. ClinicalTrials.gov. LMN-201 for prevention of C. difficile infection recurrence. ClinicalTrials.gov identifier: NCT05330182. Nov 2022 [internet publication].​Texto completo

133. Vickers RJ, Tillotson GS, Nathan R, et al. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Lancet Infect Dis. 2017 Jul;17(7):735-44.Texto completo  Resumo

134. Kokai-Kun JF, Roberts T, Coughlin O, et al. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial. Lancet Infect Dis. 2019 May;19(5):487-96. Resumo

135. McCoy RM, Klick A, Hill S, et al. Luminal toxin-binding agents for Clostridium difficile infection. J Pharm Pract. 2016 Aug;29(4):361-7. Resumo

136. Saha S, Sehgal K, Singh S, et al. Postinfection irritable bowel syndrome following Clostridioides difficile infection: a systematic-review and meta-analysis. J Clin Gastroenterol. 2022 Feb 1;56(2):e84-93. Resumo

137. Almroth S, Mohale M, Latham MC. Grandma ahead of her time: traditional ways of diarrhoea management in Lesotho. J Diarrhoeal Dis Res. 1997 Sep;15(3):167-72. Resumo

138. Brown CC, Manis MM, Bohm NM, et al. Oral vancomycin for secondary prophylaxis of Clostridium difficile infection. Ann Pharmacother. 2019 Apr;53(4):396-401. Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal